Table 2.
Clinical trials targeting MDSCs in cancer patients from ClinicalTrials.gov
| Trial number | Title | Conditions | Interventions |
|---|---|---|---|
| NCT03214718 | MDSCs and chronic myeloid leukemia | Chronic myeloid leukemia | Imatinib, nilotinib |
| NCT03302247 | Depletion of MDSCs to enhance anti-PD-1 therapy | Non-small lung cancer (stage IIIB) | Nivolumab, gemcitabine |
| NCT04022616 | MDSC function in breast cancer patients | Breast cancer | Specimen collection |
| NCT02868255 | MDSC control by signal regulatory protein-alpha: investigation in hepatocellular carcinoma | Hepatocellular carcinoma | Collection of human samples |
| NCT02916979 | MDSCs and checkpoint immune regulators’ expression in allogeneic SCT using FluBuATG | Leukemia, lymphoma, multiple myeloma | Fludarabine, busulfan, methotrexate, rabbit ATG |
| NCT02664883 | MDSC clinical assay in finding kidney cancer | Metastatic renal cell cancer, recurrent renal cell carcinoma, renal cell cancer (stage I, II, III) | - |
| NCT02669173 | Capecitabine + bevacizumab in patients with recurrent glioblastoma | Glioblastoma | Capecitabine, bevacizumab |
| NCT01803152 | Dendritic cell vaccine with or without gemcitabine pretreatment for adults and children with sarcoma | Sarcoma, soft tissue sarcoma, bone sarcoma | DC vaccine, gemcitabine, imiquimod |
| NCT03525925 | Ibrutinib and nivolumab in treating participants with metastatic solid tumors | Metastatic malignant solid neoplasm | Ibrutinib, nivolumab |
| NCT02637531 | A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 | Advanced solid tumors, non-small cell lung cancer, melanoma, squamous cell cancer of the head and neck, triple negative breast cancer, adrenocortical carcinoma, mesothelioma, high-circulating MDSCs | IPI-549, nivolumab |
| NCT03161431 | SX-682 treatment in subjects with metastatic melanoma concurrently treated with pembrolizumab | Melanoma (stage III), melanoma (stage IV) | SX-682, pembrolizumab |
| NCT03848182 | Analyzing childhood recall antigens in patients with pancreatic cancer | Pancreatic cancer | Gemcitabine, TT vaccine booster |
| NCT03961698 | Evaluation of IPI-549 combined with front-line treatments in patients with triple-negative breast cancer or renal cell carcinoma | Breast cancer, renal cell carcinoma | IPI-549, atezolizumab, nab-paclitaxel, bevacizumab |
| NCT04105335 | A study of MTL-CEBPA in combination with a PD-1 inhibitor in patients with advanced solid tumors | Solid tumor | MTL-CEBPA, pembrolizumab |
| NCT02259231 | RTA 408 capsules in patients with melanoma | Melanoma, unresectable melanoma, metastatic melanoma | Omaveloxolone, ipilimumab, nivolumab |
| NCT03301636 | A study of indoximod or placebo plus pembrolizumab or nivolumab for subjects with unresectable or metastatic melanoma | Melanoma | Pembrolizumab, nivolumab, indoximod |
MDSC, myeloid-derived suppressor cell; PD-1, programmed death-1; SCT, stem cell transplant; ATG, anti-thymocyte globulin; DC, dendritic cell; TT, tetanus toxoid.